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Abstract. Glutamate overload triggers synaptic and neuronal loss that potentially contributes to neurodegenerative dis-
eases including Alzheimer’s disease (AD). Glutamate clearance and regulation at synaptic clefts is primarily mediated by
glial glutamate transporter 1 (GLT-1). We determined that inflammatory cytokines significantly upregulated GLT-1 through
microRNA-181a-mediated post-transcriptional modifications. Unveiling the key underlying mechanisms modulating GLT-1
helps better understand its physiological and pathological interactions with cytokines. Primary murine astrocyte and neuron
co-culture received 20 ng/mL IL-1, TNF-, or IL-6 for 48 h. Soluble proteins or total RNA were extracted after treatment
for further analyses. Treatment with inflammatory cytokines, IL-1 and TNF-, but not IL-6, significantly increased GLT-1
steady-state levels (p≤ 0.05) without affecting mRNA levels, suggesting the cytokine-induced GLT-1 was regulated through
post-transcriptional modifications. Among the candidate microRNAs predicted to modulate GLT-1, only microRNA-181a
was significantly decreased following the IL-1 treatment (p≤ 0.05). Co-treatment of microRNA-181a mimic in IL-1-
treated primary astrocytes and neurons effectively blocked the IL-1-induced upregulation of GLT-1. Lastly, we attempted
to determine the link between GLT-1 and microRNA-181a in human AD brains. A significant reduction of GLT-1 was found
in AD hippocampus tissues, and the ratio of mature microRNA-181a over primary microRNA-181a had an increasing ten-
dency in AD. MicroRNA-181a controls rapid modifications of GLT-1 levels in astrocytes. Cytokine-induced inhibition of
microRNA-181a and subsequent upregulation of GLT-1 may have physiological implications in synaptic plasticity while
aberrant maturation of microRNA-181a may be involved in pathological consequences in AD.
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INTRODUCTION27
Glutamate is a major excitatory neurotransmit-28
ter in the central nervous system and plays an29
important role in modulating synaptic plasticity,30
long-term potentiation (LTP), and learning and31
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memory functions in the hippocampus. Glutamate 32
release, reuptake, and recycling are tightly executed 33
by neurons and astrocytes at tripartite synapses to 34
evoke proper post-synaptic signal transduction and 35
to prevent extensive leakage of glutamate beyond the 36
synaptic cleft. In Alzheimer’s disease (AD), gluta- 37
mate dyshomeostasis is presented by the functional 38
loss of excitatory amino acid transporter 2 (EAAT2) 39
and elevation of glutamate in the cerebrospinal 40
fluid [1–4]. Extensive alterations of glutamatergic 41
pre-synaptic boutons is also observed in a pathology- 42
dependent manner and correlates well with the 43
ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
Un
co
rre
cte
d A
uth
or
 P
ro
of
2 J. Zumkehr et al. / MicroRNA-181a Controls Cytokine-Induced GLT-1 Expression
severity of cognitive decline [5, 6] Specifically,44
impairment of glutamate reuptake results in elevated45
levels of synaptic or extrasynaptic glutamate and46
aberrant activation of synaptic and extrasynaptic N-47
methyl-D-aspartate receptors (NMDARs), leading to48
increased amyloid- (A) production [7, 8], which49
further promotes the release of glutamate and triggers50
synaptic damage [9]. In addition, mislocalization of51
tau in glutamategic synapses is shown to potentiate52
NMDAR-dependent A neurotoxicity and synaptic53
loss [10]. These findings strongly implicate that the54
loss of glutamatergic synapses is a convergence point55
that links neuropathological signatures and clinical56
manifestations, further supporting the causal role of57
glutamate dyshomeostasis in AD.58
Experimental models specifically highlight59
EAAT2 dysfunction as a critical contributor to AD.60
Genetic ablation of the glutamate transporter 161
(GLT-1), a mouse homologue of EAAT2, in a mouse62
model of AD exacerbates cognitive decline, in part63
recapitulating the above-mentioned observations in64
AD [11]. We and others have recently shown that65
A species significantly reduces GLT-1 expression66
in the plasma membrane of astrocytes [9, 12–14],67
and pharmacological or genetic restoration of GLT-168
ameliorates A or tau neuropathology and rescues69
cognition in AD mouse models [13, 14]. Together,70
these studies demonstrate that functional GLT-171
in mouse or EAAT2 in human (herein collectively72
referred to as GLT-1) is a critical factor for the73
survival of glutamatergic synapses. Thorough74
understanding of the regulatory mechanisms of75
GLT-1 expression will help elucidate the role of glu-76
tamate transporter in physiological and pathological77
conditions.78
Recent studies identified several cytokines as79
major mediators of GLT-1 expression. This regulation80
is particularly important during physiological condi-81
tions and normal brain functions as spatially-limited82
transient elevation of pro-inflammatory cytokines,83
such as IL-1, TNF-, and IL-6, has been shown84
to modulate LTP in spatiotemporal manner [15].85
While these cytokines are chronically elevated and86
dysregulated in AD [16] contribution of acute or87
chronic input of cytokines to astrocytes and underly-88
ing mechanisms to control GLT-1 expression remain89
largely unknown. Our previous findings of an age-90
dependent decrease of GLT-1 [14] in parallel with91
an increase of microRNA-181a (miR-181a) that sig-92
nificantly down-regulates several synaptic proteins93
involved in plasticity in 3xTg-AD mouse model [17]94
led us to hypothesize that miR-181a is a key mediator95
in plasticity of glutamatergic synapses by controlling 96
the expression of synaptic proteins including GLT-1 97
in astrocytes. MicroRNAs are approximately 22 98
nucleotides noncoding RNAs that bind to the 3’-UTR 99
or coding regions of their respective mRNA target 100
to control gene expression at the post-transcriptional 101
level by modulating mRNA translation and its sta- 102
bility [18]. Alterations of multiple microRNAs have 103
been implicated in AD patients and may contribute 104
to perturbing synaptic function and plasticity [19]. 105
Thus, this study investigates the role of inflammation 106
and microRNAs in controlling GLT-1 expression. 107
The aim of this study was to determine the mech- 108
anism that controls GLT-1 levels in astrocytes. When 109
murine primary astrocytes and neurons were treated 110
with IL-1 for 48 hours, the steady-state levels of 111
GLT-1 were significantly upregulated while GLT-1 112
mRNA was relatively unaffected. Among multiple 113
predicted microRNAs targeting GLT-1 mRNA, we 114
determined that miR-181a was significantly and con- 115
comitantly decreased in cytokine-treated co-culture. 116
Co-treatment of miR-181a mimics with IL-1 effec- 117
tively blocked IL-1-induced increase in GLT-1. 118
Application of miR-181a mimics alone sufficiently 119
suppressed GLT-1 in a concentration dependent man- 120
ner, confirming the role of miR-181a in silencing 121
GLT-1 expression. Lastly, we examined the poten- 122
tial involvement of miR-181a in AD by analyzing 123
GLT-1 and miR-181a in postmortem hippocampal 124
tissues from AD patients. We found that GLT-1 was 125
significantly decreased in AD brains, and the ratio 126
of mature miR-181a over primary miR-181a was 127
elevated, though not significant from controls. Our 128
results reveal that the expression of miR-181a reg- 129
ulates GLT-1 in astrocytes, and increased mature 130
miR-181a may contribute to the loss of GLT-1 in AD. 131
MATERIALS AND METHODS 132
Primary astrocyte and neuron co-culture 133
As described previously [14], primary astrocytes 134
were extracted from the cortex and hippocampus 135
of postnatal day 2-3 (P2-P3) mice from wildtype 136
(WT) mice. Primary cells were grown in Dulbecco’s 137
modified Eagle’s medium (DMEM) containing 10% 138
fetal bovine serum (FBS), 50 units/mL penicillin and 139
50g/mL streptomycin (P/S). Primary neurons were 140
extracted from embryonic day 14–16 (E14-16) of 141
WT mice. Primary neurons were added to conflu- 142
ent primary astrocytes in Neurobasal media with 2% 143
B27 supplement, glutamine, and 5% FBS (plating 144
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media) for the first 24 h then the medium was changed145
to media of similar contents but with only 2.5%146
FBS (growth media). Primary cells were treated after147
day 7 (of neuron addition). The purity of primary148
astrocytes and the presence of neurons were consis-149
tently monitored by IF staining with GFAP and Tau5150
respectively.151
Cell cultures152
Naturally secreted A monomers and oligomers153
were obtained from the conditioned medium (CM)154
of 7PA2 CHO cells that express the V717F AD155
mutation in APP751 (an APP isoform that is 751156
amino acids in length, a kind gift from Dr. Edward157
Koo, UCSD) [20]. Both control CHO cells and 7PA2158
cells were grown in the DMEM containing 10%159
FBS and P/S until ∼90% confluency. Cells were160
washed and medium replaced with neuronal growth161
media (described above) for ∼18 h. CM was collected162
and centrifuged at 1,000 × g for 10 min at 4◦C to163
remove cell debris then used for treatment of astro-164
cyte and neuron primary cell co-culture. CM from165
CHO cells and fresh growth media were used as con-166
trols. Recombinant Human Interleukin 1, beta (IL1;167
PHC0815 ThermoScientific, CA, USA).168
Quantitative measurement of secreted cytokines169
via cytokine multiplex assay170
Cytokines from CHO-CM, 7PA2-CM or growth171
media (NB) were quantified before and after 48 h172
incubation with primary neuron and astrocyte co-173
cultures. The V-PLEX Proinflammatory Panel 1174
(mouse) kits from Meso Scale Diagnostics (MSD,175
Gaithersburg, MD, USA) was used. The assay was176
performed according to the manufacturer’s instruc-177
tions and plates were analyzed on the MESO178
Quickplex SQ 120 (MSD). All standards and samples179
were measured in duplicate.180
Western blot181
Protein was extracted from primary murine astro-182
cyte and neuron co-cultures using MPER while TPER183
was used to extract protein from human hippocam-184
pal tissue (Thermo Scientific, CA, USA). Bradford185
protein assay determined protein concentrations of186
MPER- or TPER- soluble fractions. Protein extracts187
were subsequently immunoblotted with the follow-188
ing antibodies: GLT-1 (a kind gift from Dr. Jeffrey189
David Rothstein, Johns Hopkins University), IL1-190
(Biovision, CA, USA), tubulin and GAPDH (Abcam, 191
MA, USA) were used to control for protein loading 192
or to confirm no cross-contamination of each frac- 193
tion. Band intensity was measured using the Odyssey 194
Image station and Image Studio (version 2.1, Li-Cor 195
Biosciences, NE, USA) and normalized by corre- 196
sponding loading control protein. 197
RNA isolation, reverse transcription, and 198
real-time polymerase chain reaction (RT-PCR) 199
Total RNA was isolated from primary cells or 200
human hippocampal tissue using Direct-zol RNA 201
MicroPrep and Direct-zol RNA Miniprep respec- 202
tively according to manufacturer’s protocol (Zymo 203
Research Corp, CA, USA). Total RNA concentra- 204
tions were determined using a spectrophotometer 205
(NanoDrop Lite, ThermoScientific, CA, USA). 206
Purity of samples was assessed with 2100 bioana- 207
lyzer (Agilent, CA, USA). cDNA was produced from 208
1000 ng RNA using NCODE Vilo cDNA synthe- 209
sis kit (microRNAs) or SuperScript III First-Strand 210
Synthesis kit (mRNAs) following manufacturer’s 211
protocol (Life Technologies, CA, USA). SYBR green 212
detection for RT-PCR detailed protocol described 213
previously [14, 17]. The TargetScan prediction soft- 214
ware was utilized to identify microRNAs that had 215
conserved 8mer, 7mer, or 6mer target sites on the 3’ 216
UTR of SLCI1A2. 217
TaqMan detection 218
cDNA was produced from 10 ng RNA using Taq- 219
Man MicroRNA Reverse Transcription Kit (mature 220
miRNA; Catalog# 4366596, ThermoFisher, CA, 221
USA) or High-Capacity cDNA Reverse Transcription 222
Kit (primary miRNA; Catalog# 4368814, Ther- 223
moFisher, CA, USA). Quantitative RT-PCR was 224
performed using CFX Connect Real-Time System 225
(Bio-Rad, CA, USA) with the following TaqMan® 226
miRNA assays (ThermoScientific, CA, USA): hsa- 227
miR-181a (assay ID: 000480), has-miR-181b (assay 228
ID: 001098), U6 snRNA (control; assay ID: 001973), 229
hsa-mir-181a-1 (assay ID: Hs03302966 pri), hsa- 230
mir-181a-2 (assay ID: Hs03302899 pri), human 18S 231
(assay ID: Hs99999901 s1), mmu-mir-181b-1 (assay 232
ID: Mm03307120 pri), mmu-mir-181a-2 (assay ID: 233
Mm03306417 pri), and mouse Gapdh (assay ID: 234
Mm99999915 g1). Cycling for PCR amplification 235
was as follows: enzyme activation at 95◦C for 10 min, 236
followed by 45 cycles at 95◦C for 15 s and at 60◦C 237
for 60 s. 238
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MiR-181a mimic transfection239
Lipofectamine® RNAiMAX (Life Technologies,240
CA, USA) was utilized to transfect primary neuron241
and astrocyte co-culture with 15 nM, 30 nM, or 70242
nM mirVana hsa-miR-181a miRNA mimic or mir-243
Vana Negative Control #1 miRNA mimic (Ambion,244
TX, USA) per manufacturer’s protocol. Protein or245
RNA was extracted 48 h after transfection. To show246
that miR-181a mimics were upregulated in our cell247
culture after transfection, we extracted miRNAs after248
exposure and found higher levels of miR-181a in249
miR-181a (mimic) treated cells than the controls. Dif-250
ferent concentrations of miR-181a were tested based251
on previous transfection reports [17, 21].252
Statistics253
All quantitative data are expressed as254
mean ± SEM. Data analyses were obtained using255
unpaired, two-tailed t test or One-way ANOVA256
followed by post hoc tests (Holm-Sidak or Dunn’s257
multiple comparison test). The data were analyzed258
using Prism (GraphPad Prism Software) and values259
p≤ 0.05 were considered significant.260
RESULTS261
Inﬂammatory cytokines, IL-1β or TNFα,262
upregulate GLT-1 in astrocytes263
We previously reported that conditioned media264
containing naturally secreted A40 and A42 species265
from 7PA2 cells (7PA2-CM) significantly downreg-266
ulated the steady-state levels of GLT-1 compared to267
those from CHO cells lacking A species (CHO-CM)268
in primary astrocytes and neuronal co-culture [14].269
While investigating a potential molecular mecha-270
nism, we found that GLT-1 was significantly elevated271
in primary astrocyte and neuronal co-cultures treated272
with CHO-CM by 47% while 7PA2-CM still sig-273
nificantly suppressed GLT-1 steady state levels by274
36% compared to those in neurobasal media (con-275
trol) (Fig. 1). To examine the rise in GLT-1 levels276
from CHO-CM compared to control, we hypoth-277
esized that cytokines may be involved in GLT-1278
regulation since they have previously been shown279
to modulate GLT-1 expression [22, 23]. We tested a280
panel of cytokines before and after the 48-h treatment281
on our primary astrocytes and neuronal co-culture282
through MSD. While no significant differences were283
detected in selected cytokine levels among control,284
CHO-CM, and 7PA2-CM prior to the incubation 285
(data not shown), significantly elevated levels of pro- 286
inflammatory cytokines, IL-1, TNF-, IL-6, IL-5, 287
and IL-10 were found in CHO-CM, but not in con- 288
trol or 7PA2-CM, after the 48-h treatment with the 289
co-culture (Fig. 2A-E). No changes were observed in 290
IL-12p70, IFN-, IL-2, and IL-4 (data not shown). 291
We then examined whether major pro- 292
inflammatory cytokine, IL-1, TNF, or IL-6, 293
alone could modulate the levels of GLT-1. Previous 294
reports have shown independent cytokines differen- 295
tially regulate GLT-1 in a dose dependent manner [22, 296
24] thus based on these reports we chose 20 ng/mL as 297
the concentration in our treatment paradigm. Treat- 298
ment with recombinant IL-1 or TNF- (20 ng/ml) 299
significantly increased GLT-1 levels by 35% and 300
69%, respectively while recombinant IL-6 did not 301
(Fig. 3). Cytokine treatment did not alter GLT-1 302
mRNA measured by qRT-PCR (data not shown). 303
These results show that, in our treatment paradigm 304
on primary neuron and astrocyte co-cultures, specific 305
cytokines upregulate GLT-1 steady state levels while 306
having no significant effect on GLT-1 mRNA. 307
MiR-181a mediates IL-1β-induced GLT-1 308
upregulation in astrocytes 309
We continued to investigate the underlying molec- 310
ular mechanism by which IL-1 upregulated GLT-1 311
in the primary co-culture system. MicroRNAs reg- 312
ulate gene expression post-transcriptionally, and 313
several microRNAs have been reported to modu- 314
late GLT-1 expression [21, 25, 26]. Based on these 315
reports and results from Targetscan prediction search, 316
we selected 5 candidate microRNAs (20a, 29a, 107, 317
124a, and 181a) to screen for IL-1-induced GLT-1 318
upregulation. Among these candidate miRNAs, we 319
only found that miR-181a was significantly reduced 320
by 34% after 48 h of 20 ng/mL IL-1 treatment in pri- 321
mary astrocyte and neuron co-culture compared to the 322
untreated control (Fig. 4A). In addition, we quantify 323
primary miR-181a in these samples. In the mouse, the 324
miR-181 family consists of four mature microRNAs 325
(miR-181a, miR-181b, miR-181c, and miR-181d) 326
with miR-181a being transcribed from two genes 327
pri-miR-181ab1 and pri-miR-181ab2 [27, 28]. No 328
significant differences were detected in the expres- 329
sion of pri-miR-181a-1 and pri-miR-181a-2 between 330
the treatments (Fig. 4B, C) indicating that IL-1 331
directly regulates the levels of mature miR-181a. 332
We then determined whether miR-181a directly 333
suppressed GLT-1 steady state levels in vitro. We 334
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Fig. 1. GLT-1 steady state levels altered after 48 h exposure to CHO-CM or 7PA2-CM compared to control. Primary astrocyte and neuron
co-culture treated with CHO-CM elevated GLT-1 steady state levels while 7PA2-CM decreased GLT-1 steady state levels relative to regular
neurobasal growth media (control) after 48 h treatment. GLT-1 mean ± std. error: Control = 1.01 ± 0.00816, CHO-CM = 1.48 ± 0.111, 7PA2-
CM = 0.645 ± 0.0506, Control versus CHO p = 0.0023, Control versus 7PA2-CM p = 0.0051 and CHO-CM versus 7PA2-CM p < 0.0001,
n = 4 independent experiments in triplicates, and each dot represents mean of independent experiment. p≤ 0.05 considered significant by
one-way ANOVA followed by Holm-Sidak’s post hoc multiple comparisons test. Abbreviations: Con = Control; neurobasal growth media;
CHO = Chinese hamster ovary; 7PA2 = CHO cells that express the V717F AD mutation in APP751 (an APP isoform that is 751 amino acids
in length); CM = conditioned media; GLT-1 = glutamate transporter 1.
transfected miR-181a mimics to primary astrocyte335
and neuron co-culture for 48 h and found miR-181a336
mimics decreased the steady-state levels of GLT-1337
by 32% in a concentration-dependent manner com-338
pared to the vehicle (Fig. 4D). We confirmed that cells339
transfected with 70 nM miR-181a contained higher340
levels of miR-181a specifically than the control via341
RT-PCR (44 fold higher than control). Accordingly,342
we co-treated the co-culture with 20 ng/mL IL-1343
and 70 nM miR-181a mimic for 48 h, and found344
miR-181a mimics counteracted the effect of IL-1345
reducing GLT-1 steady-state levels by 48% com-346
pared to 20 ng/mL IL-1 treatment alone (Fig. 4E).347
These results show IL-1 as an external source to348
downregulate miR-181a in cells to increase GLT-1349
expression. To further explore whether the observed350
upregulation of GLT-1 by CHO-CM (Fig. 1) was pri-351
marily mediated by the downregulation of miR-181a,352
we quantified both primary and mature miR-181a353
following CHO-CM or 7PA2-CM treatment in pri-354
mary co-culture preparations. We did not find any355
significant differences in the levels of mature miR-356
181a, pri-miR181a-1, pri-miR-181a-2 or the ratios of357
mature/pri-miR-181a-1 and mature/pri-miR-181a-2358
in CHO- and 7PA2-CM compared to the control (data359
not showed), suggesting that other factors (besides360
IL1-) may modulate miR-181a expression in361
co-culture samples treated with CHO-CM.362
Loss of GLT-1 in AD brain and a possible363
contribution of mature miR-181a364
The loss of GLT-1 has been observed in post-365
mortem AD brains [2, 4]. To examine whether the366
loss of GLT-1 in AD was mediated in part by miR- 367
181a, we assessed primary and mature miR-181a 368
expression and GLT-1 steady-state levels in hip- 369
pocampal tissues from AD patients and age-matched 370
cognitively normal individuals (Table 1 for patient 371
information). We show that GLT-1 steady-state lev- 372
els were significantly reduced in AD brains by 72% 373
(Fig. 5A), consistent with previous reports [2, 4]. In 374
addition, we observed statistical significant higher 375
levels of pro-IL-1 in AD samples, consistent with 376
the well-known elevation in inflammatory responses 377
in AD brains (Fig. 5B). To correlate the loss of GLT- 378
1 with increased mature miR-181a, we quantitatively 379
measured both mature and primary miR-181a in these 380
tissues. Like in the mouse, the human miR-181 fam- 381
ily consists of four mature microRNAs (miR-181a, 382
miR-181b, miR-181c, and miR-181d) with miR-181a 383
being transcribed from pri-miR-181ab1 gene in chro- 384
mosome 1 and pri-miR-181ab2 gene in chromosome 385
2 [27, 28]. While the mean of mature miR-181a 386
between non-demented individuals and AD was not 387
different (Fig. 5C) we found lower levels of pri- 388
miR-181a-1 in AD brains compared to age matched 389
controls by 46% (Fig. 5D) but not pri-miR-181a- 390
2 (Fig. 5F) suggesting that, overall, less miR-181a 391
transcript is being produced in AD patients. Conse- 392
quently, the ratio of mature miR-181a over immature 393
form had an increasing trend in AD patients compared 394
to controls (Fig. 5E, G). 395
DISCUSSION 396
We report that miR-181a plays a pivotal role in 397
post-transcriptional modulations of GLT-1 in astro- 398
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Fig. 2. Significant differences in cytokine profile between CHO- and 7PA2-CM after 48 h of exposure to co-culture. (A) IL-1 levels in pg/mL
(mean ± std. error: Control = 0.170 ± 0.0422, CHO-CM = 1.13 ± 0.182, 7PA2-CM = 0.0969 ± 0.0165), (B) TNF- (Control = 147 ± 8.17,
CHO-CM = 833 ± 166, 7PA2 = 46.5 ± 5.92), (C) IL-6 (Control = 154 ± 4.79, CHO-CM = 3320 ± 607, 7PA2 = 75.2 ± 5.03), (D) IL-5 (Con-
trol = 0.407 ± 0.174, CHO-CM = 3.66 ± 0.675, 7PA2 = 1.55 ± 0.759), and (E) IL-10 (Control = 1.82 ± 0.199, CHO-CM = 37.1 ± 5.94,
7PA2 = 1.57 ± 0.108). n = 3-4 independent experiments in duplicates, and each dot represents mean of independent experiment. p≤ 0.05
considered significant by one-way ANOVA followed by Sidak’s post hoc multiple comparison’s test.
cytes. IL-1 and TNF-, but not IL-6, significantly399
upregulated GLT-1 levels, and particularly IL-1-400
induced GLT-1 was mediated by down-regulation of401
miR-181a in the primary neuron and astrocyte co-402
culture. Lastly, we examined whether miR-181a was403
involved in pathological loss of GLT-1 in AD. In 404
agreement with previous studies [2, 4, 29], GLT- 405
1 decreased in the hippocampus from advanced 406
stages of AD patients compared to age-matched non- 407
demented individuals. In these tissues, we found a 408
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Fig. 3. Synthetic recombinant 20 ng/mL IL-1 or TNF- increase GLT-1 but not IL-6 after 48 h exposure compared to control. GLT-1
mean ± std. error: Control = 1.01 ± 0.00332, TNF-= 1.71 ± 0.271; p = 0.0128, IL-1= 1.36 ± 0.0797; p = 0.0427, IL-6 = 1.07 ± 0.0172;
p > 0.9999. n = 2–4 independent experiments in duplicates or triplicates, and each dot represents mean of independent experiment. p≤ 0.05
considered significant by one-way ANOVA followed by Dunn’s post hoc multiple comparison’s test.
trend toward increasing ratio of mature miR-181a409
over primary miR-181a in AD brains when com-410
pared to age-matched control brains, suggesting that411
aberrant maturation of miR-181a could be early412
pathological changes during the disease course.413
IL-1-mediated GLT-1 regulation may elicit a414
wide spectrum of effects because of the involvement415
of various pathways and duration of exposure. In416
comparison to our results, others have shown that417
IL-1 decreases GLT-1 [22], however this dichoto-418
mous effect on GLT-1 may be in part owing to the419
concentration of cytokines [15], diversity of mod-420
els (single versus co-cultures) [30], exposure time421
[15, 30], serum use [31], and differential regula-422
tion between protein and mRNA. Specifically, the423
binding of IL-1 to the IL-1 receptor 1 (IL-1R1) fol-424
lowed by recruitment of accessory protein subunit425
expressed on astrocytes can ultimately activate tran-426
scription factors including NF-κB [32, 33]. NF-κB in427
turn can bind to multiple binding sites available on428
the GLT-1 promoter; however, distinct pathways can429
repress or activate GLT-1 expression depending on430
the co-factors present [23, 34]. Further complicating431
a succinct conclusion among reports but indicating a432
need to explore other regulatory pathways mediated433
by IL-1. Thus, we explored and convincingly show434
that IL-1 regulates GLT-1 post-transcriptionally via435
microRNAs.436
The duration of our experimental conditions per-437
formed in our in vitro studies is acute and not in the438
chronic state of IL-1 treatment that mimics the dis-439
ease state commonly observed in AD. In this regard,440
our experimental condition may represent in part a441
physiological state with transient elevation of IL-1442
and other local cytokines. Such acute treatment of443
cytokines, specifically IL-1, may relay essential sig-444
nals from local microenvironment to astrocytes to445
adapt their functions. In the presence of astrocytes, 446
GLT-1 upregulation can be a compensatory mecha- 447
nism to prevent sustained NMDAR activity indicating 448
a neuron-glia crosstalk. As others have demonstrated 449
that IL-1 increases activity of NMDAR in a manner 450
sufficient to increase neuronal cell death in neuronal 451
cultures [35]. The effect of IL-1 seen in our treat- 452
ment paradigm on astrocytes and neurons may be 453
to control glutamate levels by modulating astrocytic 454
GLT-1 expression at the synapse. 455
While IL-1 has been shown to suppress LTP on 456
primary neuronal cultures and hippocampal slices 457
[15, 36–38], other studies show that IL-1 is impor- 458
tant and essential for LTP. Specifically, IL-1R1 459
deficient mice develop memory impairment and/or 460
LTP inhibition [39, 40]. This impairment was res- 461
cued by introducing wildtype astrocytes in the IL-1R1 462
deficient mice [41]. Moreover, IL-1 expression 463
significantly increases following LTP and learning 464
[42]. In addition, GLT-1 is responsible for glutamate 465
uptake during LTP and pharmacological inhibition of 466
astrocytic GLT-1 activity reduced LTP and prevented 467
induction of additional LTP in hippocampal slices 468
and cell culture experiments [43], suggesting that 469
GLT-1 plays an important role in synaptic plasticity. 470
MiR-181a is enriched in neurons and astrocytes par- 471
ticularly in the hippocampus and is critically involved 472
in synaptic plasticity and memory processing [17, 473
27, 44]. Recent growing bodies of evidence strongly 474
implicate spatiotemporal maturation of precursor 475
microRNA to mature miR-181a at the synaptic com- 476
partment during low-frequency stimulation, which 477
subsequently down-regulates CAMKII [44]. Other 478
critical plasticity-related proteins regulated by miR- 479
181a include cFos and SIRT1 [17, 44]. Thus, at the 480
tripartite synapse, the activity-dependent maturation 481
of miR-181a rapidly changes synaptic constituents 482
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Fig. 4. IL-1 increases GLT-1 steady state levels via miR-181a. (A) TaqMan® Chemistry for RT-PCR using miR-181a primer shows 48 h
exposure of 20 ng/mL IL-1 downregulates miR-181a; GLT-1 mean ± std. mean error: Control = 1.31 ± 0.0980 and IL-1= 0.864 ± 0.113,
p = 0.0249. n = 4 independent experiments in triplicates, and each dot represents mean of independent experiment. p≤ 0.05 con-
sidered significant by unpaired t-test. (B) No significant differences were observed in mmu-pri-miR-181a-1 (Control = 1 ± 0.35 and
IL-1= 1.08 ± 0.46, p = 0.89) or mmu-pri-miR-181a-2 (Control = 1 ± 0.21 and IL-1= 1.41 ± 0.29, p = 0.32) (C). (D) miR-181a mimic
decreases GLT-1 expression compared to the vehicle in a concentration-dependent manner after 48 h. GLT-1 mean ± std. error: Vehi-
cle = 1.03 ± 0.0102, Control = 1.02 ± 0.0882, 15 nM = 1.056 ± 0.0813, 30 nM = 0.875 ± 0.0149, 70 nM = 0.701 ± 0.0509 (p = 0.0102),
negative control = 0.953 ± .0983. n = 5 independent experiments with duplicates or triplicates, and each dot represents mean of independent
experiment. p≤ 0.05 considered significant by one-way ANOVA followed by Dunn’s post hoc multiple comparison’s test. (E) Co-treatment
of 70 nM miR-181a mimic with 20 ng/mL IL-1 after 48 h returned GLT-1 steady state levels relatively close to control levels. GLT-
1 mean ± std. error: Control = 1.00 ± 0.00241, IL-1= 1.81 ± 0.280, IL-1 and miR-181a mimic = 0.935 ± 0.0705; Control versus IL-1
(p = 0.0149), IL-1 versus IL-1 and 70 nM miR-181a mimic (p = 0.0143). n = 4 independent experiments in duplicates or triplicates, and
each dot represents mean of independent experiment. p≤ 0.05 considered significant by one-way ANOVA followed by Holm-Sidak’s post hoc
multiple comparison’s test. miR-181a mimic = mirVana hsa-miR-181a-5p and scramble = mirVana Negative Control #1 microRNA mimic.
Table 1
Human samples information
Neuropathology Dx Mean age (y) MMSE Plaque Stage Tangle Stage n*
Control 83 – 87 22 – 30 A-C 3–5 6 – 8
AD 80 – 90 10 – 17 A-C 4–6 6 – 8
*equal number of males and females.
and post-synaptic signaling cascades. This body of483
work shows that IL1-, GLT-1 and miR-181a are all484
important regulators of synaptic plasticity. Together485
with our results presented herein the interesting pos-486
sibility emerges that IL-1-mediated upregulation of487
GLT-1 via downregulation of miR-181a may be part488
of the mechanisms involved in LTP and synaptic plas- 489
ticity. Augmented levels of GLT-1 would be required 490
to deal with the increased activity associated with 491
strengthened synapses and to avoid neurotoxicity. 492
However, this hypothesis remains to be explored and 493
further studies are needed to validate our results under 494
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Fig. 5. GLT-1, pro-IL-1, and miR-181a levels in hippocampal human samples. GLT-1 steady state levels and microRNA levels from
hippocampal human AD patients compared to age-matched controls. A) GLT-1 steady state levels significantly decrease in AD human patients
compared to age-matched human controls. GLT-1 mean ± std. mean error: Control = 1.32 ± 0.489 and AD = 0.370 ± 0.0975 (p = 0.0127).
B) pro-IL-1 steady state levels were significantly increased in AD human patients compared to age-matched human controls. Pro-IL-1
control = 1 ± 0.09 and AD = 1.3 ± 0.10 (p = 0.05). C) No significant differences between mature miR-181a levels from AD patients compared
to age-matched control. miR-181a mean ± std. mean error: Control = 0.967 ± 0.162 and AD = 0.837 ± 0.179 (p = 0.7789). D) Decrease of
immature miR-181a levels in AD compared to age matched control. pri-miR-181a-1 mean ± std. mean error: Control = 0.533 ± 0.0919,
AD = 0.2857 ± 0.0962 (p = 0.0927). E) Ratio of mature miR-181a and pri-miR181a-1 is higher in AD compared to age matched control
groups. Control = 1.92 ± 0.469, AD = 3.95 ± 0.944 (p = 0.228). F) No differences in pri-miR-181a-2 levels between AD and age matched
controls. pri-miR-181a-2 mean ± std. mean error: Control = 0.540 ± 0.103, AD = 0.563 ± 0.166 (p = 0.758) and (G) ratio of miR-181a and
pri-miR-181-a-2 ± std. mean error: Control = 1.70 ± 0.410, AD = 2.70 ± 0.748 (p = 0.622). Each symbol represents 1 human sample with
an ID corresponding to the number next to the symbol (ntotal = 5 – 8 samples). p≤ 0.05 considered significant by unpaired t-test. Immature
miR-181a corresponds to primary miR-181a.
relevant physiological conditions using appropriate495
in vivo models.496
In addition to its role in dynamic physiological497
mechanisms, microRNAs are increasingly recog-498
nized as important biomarker for various diseases499
[45]. In AD, reduction of miR-181a was initially500
reported in the cerebrospinal fluid compared to the 501
age-matched controls [46]. More recently, as a part 502
of identification of plasma biomarkers for AD, miR- 503
181a appeared as one of novel microRNAs that are 504
significantly different when compared between con- 505
trol and MCI or early-stage AD, but not established 506
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AD [47], suggesting that miR-181a may be involved507
in the prodromal or early stages of AD pathogenesis,508
possibly when synaptic abnormalities are being trig-509
gered. We attempted to determine the levels of mature510
miR-181a in post-mortem AD brains. Although we511
detected an increasing trend of mature miR-181a512
ratio in AD, it failed to show statistical significance,513
possibly because these brains were from relatively514
advanced stages of AD. Further studies will be needed515
to extensively analyze the microRNA profile in brain516
tissues from MCI and early stages of AD patients.517
Conclusion518
Insurmountable evidence of GLT-1’s importance in519
maintaining a healthy microenvironment in normal520
aging brains and the consequences that may result521
from its dysfunction has led to GLT-1 being a poten-522
tial target for therapeutic interventions for AD. Our523
approach simplifies a very complex system but has524
allowed us to focus on important components that525
unveil a potential molecular mechanism that affect526
GLT-1 steady state level expression. Our in vitro527
study is a primary step to unveiling a potential and528
important molecular mechanism that regulates GLT-529
1 steady state levels. Further studies are needed to530
extrapolate our results and apply them in a more531
complex model. In conclusion, we provide a bene-532
ficial role of inflammatory cytokines and suggest that533
this may be a defense mechanism against a possible534
neurotoxic environment.535
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